PURE Bioscience Short Interest Ratio and Short Volume

PURE Bioscience (OTCMKTS:PURE) Short Interest Frequently Asked Questions

What is PURE Bioscience's current short interest?

Short interest is the volume of PURE Bioscience shares that have been sold short but have not yet been covered or closed out. As of September 30th, investors have sold 3,800 shares of PURE short. Learn More on PURE Bioscience's current short interest.

Is PURE Bioscience's short interest increasing or decreasing?

PURE Bioscience saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 3,800 shares, a decline of 86.9% from the previous total of 29,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does PURE Bioscience's short interest compare to its competitors?

0.00% of PURE Bioscience's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to PURE Bioscience: Orgenesis Inc. (1.91%), NervGen Pharma Corp. (0.00%), Cyclerion Therapeutics, Inc. (0.00%), Odonate Therapeutics, Inc. (2.01%), Hepion Pharmaceuticals, Inc. (2.27%), Second Sight Medical Products, Inc. (0.00%), Freeline Therapeutics Holdings plc (0.23%), Genprex, Inc. (0.00%), Applied Genetic Technologies Co. (8.52%), and Skylight Health Group Inc. (0.47%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($7.35 billion), Advanced Micro Devices, Inc. ($6.43 billion), Charter Communications, Inc. ($5.68 billion), Wayfair Inc. ($4.48 billion), Uber Technologies, Inc. ($3.77 billion), Canadian Pacific Railway Limited ($3.73 billion), Palo Alto Networks, Inc. ($3.10 billion), Zoom Video Communications, Inc. ($2.87 billion), Match Group, Inc. ($2.83 billion), and DoorDash, Inc. ($2.54 billion). View all of the most shorted stocks.

What does it mean to sell short PURE Bioscience stock?

Short selling PURE is an investing strategy that aims to generate trading profit from PURE Bioscience as its price is falling. PURE Bioscience's stock is trading up $0.04 today. To short PURE Bioscience stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that PURE Bioscience will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against PURE Bioscience?

A short squeeze for PURE Bioscience occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PURE, which in turn drives the price of the stock up even further.

How often is PURE Bioscience's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PURE, twice per month. The most recent reporting period available is September, 30 2021.